32 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
to in the biopharmaceutical community as small molecules, but our BiDAC degraders tend to be larger than traditional small molecule therapeutics. We have selected … supporting our local community in their efforts to bridge the opportunity gap for underserved communities. With assistance from our Diversity, Equity
ARS
jrh1qzb mfrts
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
9x8ue
18 Apr 23
Preliminary proxy
7:59am
424B4
793xw mskbd07w
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
qjvikh9 kar41ql6
19 May 21
Draft registration statement
12:00am